Arsh Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.10 Cr
as on 07-07-2024
- Paid Up Capital ₹ 1.00 Cr
as on 07-07-2024
- Company Age 10 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 88.50%
(FY 2022)
- Profit 184.00%
(FY 2022)
- Ebitda 91.54%
(FY 2022)
- Net Worth 43.61%
(FY 2022)
- Total Assets -43.33%
(FY 2022)
About Arsh Biotech
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.10 Cr and a paid-up capital of Rs 1.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Mangla Sahni and Rajan Sahni serve as directors at the Company.
- CIN/LLPIN
U24100DL2014PTC264996
- Company No.
264996
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Feb 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Arsh Biotech Private Limited offer?
Arsh Biotech Private Limited offers a wide range of products and services, including Natural Flowers, Carnation Flower, Rapid Test Kit, Elisa Kits, Fresh Flower, Gladiolus Flower, Fresh Vegetables, Tomato, Fresh Flowers, Plants & Trees, Flowering Plant.
Who are the key members and board of directors at Arsh Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mangla Sahni  | Director | 18-Feb-2014 | Current |
| Rajan Sahni | Director | 18-Feb-2014 | Current |
Financial Performance of Arsh Biotech.
Arsh Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 88.5% increase. The company also saw a substantial improvement in profitability, with a 184% increase in profit. The company's net worth Soared by an impressive increase of 43.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arsh Biotech?
In 2022, Arsh Biotech had a promoter holding of 98.99% and a public holding of 1.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
_PRIVATE_LIMITED.webp)
Life Technologies (India) Private LimitedActive 22 years 11 monthsMangla Sahni and Rajan Sahni are mutual person
Atz Lab Solutions (India) Private LimitedActive 27 years 4 monthsMangla Sahni and Rajan Sahni are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Arsh Biotech?
Unlock and access historical data on people associated with Arsh Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arsh Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arsh Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
